Psychiatric Times March 23, 2024
From the relationship between glucose fluctuations and cognition in patients with type 1 diabetes to augmentation strategies for treatment-resistant depression, here are highlights from the week in Psychiatric Times.
This week, Psychiatric Times® discussed a wide variety of psychiatric issues and industry updates, from the relationship between glucose fluctuations and cognition in patients with type 1 diabetes to augmentation strategies for treatment-resistant depression.
First Patient Screened Ahead of Schedule in Phase 2 Clinical Trial of Therapeutic Candidate for Schizophrenia
The first patient in a placebo-controlled, phase 2 clinical study of Anavex®3-71 for the treatment of the positive, negative, and cognitive domains of schizophrenia has been screened ahead of schedule. The therapeutic candidate was approved by the US Food and Drug...
Today's Sponsors
Today's Sponsor